A Quality by Design Approach to Microbial Retention Validation

References

1. 1.↵
   1. Juran J. M.

   Juran on Quality by Design: The New Steps for Planning Quality into Goods and Services; Simon and Schuster, 1992.
2. 2.↵
   1. Rathore A. S.,
   2. Winkle H.

   Quality by Design for Biopharmaceuticals. Nat. Biotechnol. 2009, 27 (1), 26–34.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   International Conference for Harmonisation, Quality Guideline Q8(R2): Pharmaceutical Development. ICH: Geneva, 2009.
4. 4.↵
   International Conference for Harmonisation, Quality Guideline Q9 Quality Risk Management Step 4. ICH: Geneva, 2005.
5. 5.↵
   International Conference for Harmonisation, Quality Guideline Q10 Pharmaceutical Quality. Step 4. ICH: Geneva, 2008.
6. 6.↵
   CMC Biotech Working Group. A-Mab: A Case Study in Bioprocess Development, v2.1. CASSS: Emeryville, CA, 2009.
7. 7.↵
   1. Alt N.,
   2. Zhang T. Y.,
   3. Motchnik P.,
   4. Taticek R.,
   5. Quarmby V.,
   6. Schlothauer T.,
   7. Beck H.,
   8. Emrich T.,
   9. Harris R. J.

   Determination of Critical Quality Attributes for Monoclonal Antibodies Using Quality by Design Principles. Biologicals 2016, 44 (5), 291–305.

   OpenUrl
8. 8.↵
   Committee for Medicinal Products for Human Use (CHMP). Assessment Report, Perjeta, EMA/17250/2013. EMA: London, 2012.
9. 9.↵
   1. Finkler C.,
   2. Krummen L.

   Introduction to the Application of QbD Principles for the Development of Monoclonal Antibodies. Biologicals 2016, 44 (5), 282–290.

   OpenUrl
10. 10.↵
    1. Hakemeyer C.,
    2. McKnight N.,
    3. St. John R.,
    4. Meier S.,
    5. Trexler-Schmidt M.,
    6. Kelley B.,
    7. Zettl F.,
    8. Puskeiler R.,
    9. Kleinjans A.,
    10. Lim F.,
    11. Wurth C.

    Process Characterization and Design Space Definition. Biologicals 2016, 44 (5), 306–318.

    OpenUrl
11. 11.↵
    1. Kelley B.,
    2. Cromwell M.,
    3. Jerkins J.

    Integration of QbD Risk Assessment Tools and Overall Risk Management. Biologicals 2016, 44 (5), 341–351.

    OpenUrl
12. 12.↵
    1. Kepert J. F.,
    2. Cromwell M.,
    3. Engler N.,
    4. Finkler C.,
    5. Gellerman G.,
    6. Gennaro L.,
    7. Harris R.,
    8. Iverson R.,
    9. Kelley B.,
    10. Krummen L.,
    11. McKnight N.,
    12. Motchnik P.,
    13. Schnaible V.,
    14. Taticek R.

    Establishing a Control System Using QbD Principles. Biologicals 2016, 44 (5), 319–331.

    OpenUrl
13. 13.↵
    1. Kan S.,
    2. Lu J.,
    3. Liu J.,
    4. Wang J.,
    5. Zhao Y.

    A Quality by Design (QbD) Case Study on Enteric-Coated Pellets: Screening of Critical Variables and Establishment of Design Space at Laboratory Scale. Asian J. Pharm. Sci. 2014, 9 (5), 268–278.

    OpenUrl
14. 14.↵
    Parenteral Drug Association Inc. Technical Report No. 26: Sterilizing Filtration of Liquids; Bethesda, MD, 2008.
15. 15.↵
    1. Peterson W.

    The Use of Scientific Data to Assess and Control Risks Associated with Sterilizing Filtration. PDA Letter 2020.
16. 16.↵
    ASTM International. ASTM F838-20 Standard Test Method for Determining Bacterial Retention of Membrane Filters Utilized for Liquid Filtration. ASTM: West Conshohocken, PA, 2020.
17. 17.↵
    1. Leahy T. L.,
    2. Sullivan M. J.

    Validation of Bacterial-Retention Capabilities of Membrane Filters. Pharm. Technol. 1978, 2 (11), 64–75.

    OpenUrl
18. 18.↵
    1. Leahy T. L.

    Validation of Bacterial Retention by Membrane Filtration: A Proposed Approach for Determining Sterility Assurance. PhD Thesis, Univ. Massachusetts, Plant and Soil Sciences Dept., Amherst, MA. 1983.
19. 19.↵
    1. Johnston P. R.,
    2. Schroeder H. G.

    1. Levy R. V.

    The Effects of pH, Viscosity and Additives on the Bacterial Retention of Membrane Filters Challenged with Pseudomonas diminuta. In Fluid Filtration: Liquid; Johnston P. R., Schroeder H. G., Eds.; ASTM Special Technical Publication No. 975; ASTM: Philadelphia, PA, 1987; 80–89, Vol. II.
20. 20.↵
    1. Levy R. V.,
    2. Souza K. S.,
    3. Hyde D. L.,
    4. Gambale S. M.,
    5. Neville C. B.

    The Matrix Approach: Microbial Retention Testing of Sterilizing-Grade Filters with Final Parenteral Products, Part II. Pharm. Technol. 1991, 15 (5), 58–68.

    OpenUrl
21. 21.↵
    1. Aicholtz P.,
    2. Wilkins R.,
    3. Gabler R.

    Sterile Filtration under Conditions of High Pressure and Bacterial Challenge Levels. J. Parenter. Sci. Technol. 1987, 41 (4), 117–120.

    OpenUrlPubMed
22. 22.↵
    EMD Millipore Corporation. Durapore Cartridge Filter Validation Guide, VG001 Rev D 10/2012. 2012.
23. 23.↵
    EMD Millipore Corporation. Retention of Small Organisms by 0.22 μm Durapore^® Filter: A Study on Bacterial Retention to Determine the Worst Case Challenge Organism Lit No AN6310EN 08/2020.
24. 24.↵
    1. Holstein M.,
    2. Hung J.,
    3. Feroz H.,
    4. Ranjan S.,
    5. Du C.,
    6. Ghose S.,
    7. Li Z. J.

    Strategies for High-Concentration Drug Substance Manufacturing to Facilitate Subcutaneous Administration: A Review. Biotechnol. Bioeng. 2020, 117 (11), 3591–3606.

    OpenUrl
25. 25.↵
    1. DiMasi J. A.,
    2. Grabowski H. G.,
    3. Hansen R. W.

    Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. J. Health Econ. 2016, 47, 20–33.

    OpenUrlCrossRefPubMed
26. 26.↵
    U.S. Pharmacopeial Convention, General Chapter <71> Sterility Tests. In USP 42—NF 37, USP: Rockville, MD, 2019.
27. 27.↵
    U.S. Food and Drug Administration, 21 CFR Part 211 –Current Good Manufacturing Practice for Finished Pharmaceuticals, Subpart 113(b) Control of Microbiological Contamination. U.S. Department of Health and Human Services. Government Publishing Office: Washington, D.C., 1995.
28. 28.↵
    U.S. Food and Drug Administration. Guidance for Industry: Current Good Manufacturing Practice for Phase 1 Investigational Drugs, FDA-2005-D-0157. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2008.
29. 29.↵
    European Commission. EudraLex—The Rules Governing Medicinal Products in the European Union, Volume 4: Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 13, Investigational Medicinal Products, Section 17 [ENTR/F/2/AM/an D (2010) 3374], European Commission: Brussels, 2010.
30. 30.↵
    U.S. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2004.